All In Biotech

Drug Trial Radar · NCT04762355

Study to Assess Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Palovarotene Ophthalmic Solution in Healthy Adult Subjects

A Phase 1, Double-Masked, Vehicle-Controlled Study to Assess Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Palovarotene Ophthalmic Solution in Healthy Adult Subjects

Last checked: Nov 20, 2026Latest source record: Feb 21, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

48

Actual

Start

Aug 30, 2018

Primary completion

Jan 3, 2019

Study completion Jan 3, 2019

Sponsor

Lead sponsor
Clementia Pharmaceuticals Inc.Industry
Sponsor type
Industry
Collaborators
Ipsen
First posted
Feb 21, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Dry eye disease (DED) is a keratoconjunctive disorder that "is a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. The goal of this study is to assess the safety, tolerability, and pharmacokinetics (PK) of multiple ascending doses of palovarotene ophthalmic solution in healthy adult subjects.

Conditions

  • Dry Eye Disease

Interventions

  • PalovaroteneDrug

    ophthalmic solution in different concentrations: Dose 1, Dose 2 and Dose 3

  • VehicleDrug

    Placebo-to-match palovarotene ophthalmic solution vials

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number and severity of treatment-emergent ocular adverse events (TEAEs)Time frame: from baseline until the end of study (up to 25 days)
  2. Change in ocular safety measurements as determined by Best-Corrected Visual Acuity (BCVA)Time frame: from baseline until the end of study (up to 25 days)
  3. Change in Corneal Fluorescein StainingTime frame: from baseline until the end of study (up to 25 days)
  4. Change in intraocular pressureTime frame: from baseline until the end of study (up to 25 days)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Algorithme Pharma facility

    Québec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.